Research programme: immune modulation therapy - Immune NetworkAlternative Names: Immune modulation therapy research programme - Immune Network
Latest Information Update: 22 Apr 2003
At a glance
- Originator Immune Network
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 13 Apr 2000 Preclinical development for Hepatitis C in Canada (Unknown route)